Tag Archives: Amgen

Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

After the late Rep. Elijah Cummings launched a drug pricing probe of some of the industry’s largest players last January, six pharmaceutical execs are set to head to Washington next week for hearings at the House Committee on Oversight and Reform.  Current and former executives from Celgene, Bristol Myers Squibb, Teva, Amgen, Mallinckrodt and Novartis will testify next Wednesday… Read More »

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON (Reuters) – Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. FILE PHOTO: An Amgen sign is seen at… Read More »

Locked in a Sensipar patent fight, Teva rolled its generic anyway—and then Amgen settled

Amgen has been sweating potential copycats to its blockbuster calcium reducer Sensipar. But thanks to a patent deal with Teva, yet another challenger will have to wait until 2021 to sell its generic knockoff. This deal features a unique wrinkle, though. Teva had already launched its version, according to Bernstein analyst Ronny Gal, costing Amgen tens… Read More »

Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters, at a big discount

After experiencing slow uptake for its first biosim launch, Pfizer isn’t giving up on the budding field. On Wednesday, the drugmaker introduced its third biosim, and second in two months, launching anemia treatment Retacrit at a significant discount to Amgen’s Epogen and Johnson & Johnson’s Procrit. Pfizer started shipping Retacrit to wholesalers on Monday at… Read More »